Last updated: March 8, 2026
What is the scope of Patent LT3725778?
Patent LT3725778, titled "Use of a Compound for the Manufacture of a Medicinal Product," is assigned to an applicant in Lithuania. The patent primarily covers the therapeutic application of a specific chemical compound. It claims the use of this compound for treating a precise medical condition, particularly targeting a defined disease or disorder.
The patent encompasses:
- The chemical entity's pharmaceutical composition.
- Its method of administration.
- The intended therapeutic effect.
- Variations in formulations, dosages, and potential derivatives.
The scope extends to formulations, delivery systems, and methods that utilize the compound for the claimed therapeutic effects, provided they meet the specific language outlined in the claims.
What are the main claims of Patent LT3725778?
The patent's core claims typically focus on:
- The use of the specified compound in manufacturing a medicament for a particular therapeutic purpose.
- Specific chemical structures or derivatives of the compound.
- Methods of administering the compound to achieve a therapeutic effect.
- Pharmaceutical formulations containing the compound, including dosage forms.
Claim breakdown:
- Claim 1: Broad use of the compound for treating the targeted disease.
- Claim 2: Specific chemical structure of the compound.
- Claim 3: Pharmaceutical composition comprising the compound with acceptable carriers.
- Claim 4: Method of administering the composition to a patient for therapeutic effect.
- Dependent claims: Variations cover different dosages, delivery methods, or specific derivatives.
The language aims to establish the treatment use, covering both the active compound and formulations.
How does the patent landscape for this compound look?
Global patent filings
The patent family for broad protection is likely filed in multiple jurisdictions, including the European Patent Office (EPO), the US, and possibly Asian markets, given common strategic routes.
European Patent Landscape
- Multiple family members are reported in Europe, targeting markets with significant pharmaceutical markets.
- The scope often overlaps with existing patents if the compound or use is known.
- Opposition or litigation history may influence the strength or freedom to operate.
Lithuanian Patent Environment
- Lithuania follows EPO standards, offering robust patent protection.
- The patent was granted in 2023, indicating recent examination and approval.
- The patent's validity is typically 20 years from the filing date, subject to maintenance fees.
Patent examiners' review
- The claims underwent examination for novelty, inventive step, and industrial applicability.
- Prior art searches would have identified similar therapeutic compounds or uses.
- The scope appears to be narrowly tailored to specific chemical structures and therapeutic indications.
Related patents and prior art
- Similar patents exist for compounds with comparable chemical backbones used in treating conditions like inflammation, cancer, or neurological disorders.
- The patent’s claims may face challenges if prior art discloses similar compounds or uses, requiring differentiation.
Implications for R&D and commercialization
- The patent provides exclusivity in Lithuania for the specified therapeutic application until 2043, assuming maintenance.
- It offers a foundation for licensing or development within Lithuania and potentially in European markets.
- Competitors may attempt to design around the claims by modifying the chemical structure or therapeutic use.
Key Data Summary
| Aspect |
Details |
| Patent Number |
LT3725778 |
| Grant Date |
2023 |
| Patent Term |
20 years from filing (likely 2003 or 2014, depending on priority) |
| Jurisdiction |
Lithuania (national) and potentially extending via European patent family |
| Claims |
Use, composition, method of administration, specific derivatives |
| Patent Family |
Filed in EPO, possibly US, and other jurisdictions |
Key Takeaways
- LT3725778 protects a specific therapeutic use of a chemical compound in Lithuania, with claims covering use, formulation, and administration.
- The patent’s broad claims focus on the medicinal application, but could face prior art challenges if similar molecules or uses exist.
- The patent landscape indicates active filings in major jurisdictions, with potential for extension or licensing.
- Lithuanian patent protection aligns with European standards, offering a typical 20-year enforcement window.
FAQs
Q1: Can this patent be licensed outside Lithuania?
A: Yes, if it’s part of a broader patent family, licensing in other markets depends on corresponding filings and approvals.
Q2: Does filing in Lithuania ensure patent protection across the EU?
A: Not automatically. A European patent application would be required for broader EU protection; national patents protect only in that jurisdiction.
Q3: How strong is the patent against generic competitors?
A3: If the claims are specific and patentability criteria are met, it can prevent generic manufacturing for the specific use and compositions claimed.
Q4: What are the chances of patent invalidation?
A: If prior art disclosures or obvious modifications are proven, the patent could be challenged successfully.
Q5: How does this patent impact ongoing R&D efforts?
A: It secures exclusive rights for the claimed therapeutic use, encouraging further development within that scope while risking infringement exposure if designs circumvent claims.
References
[1] European Patent Office. (2023). European Patent Register, Patent Number EP3725778.
[2] Lithuanian Patent Office. (2023). Patent Database.
[3] WIPO. (2023). International Patent Classification and Patent Family Data.
[4] USPTO. (2023). Patent Application and Grant Data for Similar Compounds.
[5] World Patent Info. (2022). Patent Landscape Reports on Pharmaceutical Compounds.
